Healthcare Services Group Shares Rise 13% on Q1 Earnings and Quarterly Dividend Increase
Source: Streetwise Reports  (4/21/21)
Healthcare Services Group Inc.'s shares traded 13% higher after the company reported Q1/21 financial results that included a 22% YoY increase in net income. More >

Is the Trend Turning for This Psychedelic Stock?
Source: Clive Maund for Streetwise Reports  (4/19/21)
Technical analyst Clive Maund charts Delic Inc. and explains why he considers the stock attractive at this point. More >

Merck Selects Rapidly Growing Psychedelic Medicine Company as Key Research Site
Source: Streetwise Reports  (4/16/21)
Novamind runs clinics, research sites and therapeutic retreats and is positioning itself for expansion. More >

Health Tech Company Acquiring Ontario Health Management Firm, Its Largest Transaction Ever
Source: Streetwise Reports  (4/16/21)
A Research Capital Corp. report discusses CloudMD Software & Services' acquisition of Oncidium, "one of Canada's leading health
management companies." More >

Ardelyx to Receive $5M Milestone Payment as Japan Partner Initiates Phase 3
Source: Streetwise Reports  (4/15/21)
Ardelyx Inc. shares traded 11% higher after Kyowa Kirin Co. Ltd., its collaborative partner in Japan, initiated four Phase 3 clinical trials of tenapanor for treatment of hyperphosphatemia. More >

Biotech Company Acquires Therapeutics Firm, Gains 'Gem' in the Portfolio
Source: Streetwise Reports  (4/14/21)
Dawson James Securities advised it is maintaining its "Buy" rating after Sorrento Therapeutics announced the acquisition of ACEA Therapeutics for $38 million in stock. More >

Novocure Shares Climb 50% on Acceleration of Phase 3 Lung Cancer Trial
Source: Streetwise Reports  (4/13/21)
Novocure Ltd. shares reached a new 52-week high after the company reported an update from its Phase 3 Pivotal LUNAR trial of tumor treating electrical fields in non-small cell lung cancer. More >

Affimed NV Shares Rise 20% on Initial Data from Phase 1 R/R CD30-Positive Lymphoma Trial
Source: Streetwise Reports  (4/9/21)
Affimed NV shares reached a new 52-week high price after the company presented initial data from a Phase 1 trial of its AFM13 that shows potential to help NK cells target and destroy cancer cells. More >

Gene Therapy Restoring Light Sensitivity 'Showed Impressive Dose-Response Improvements'
Source: Streetwise Reports  (4/7/21)
Roth Capital Partners advised that Applied Genetic Technologies co-development of BS01 with Bionic Sight "validates its gene therapy capabilities." More >

Biopharma's Phase 2b/3 Alzheimer's Disease Trial Approved to Continue
Source: Streetwise Reports  (4/7/21)
Anavex Life Sciences' study, its drug's mechanism of action and the company's upcoming catalysts are covered in a Dawson James Securities report. More >

Biohaven Expects Net Revenue of $43.8 Million in Q1 for Its Migraine Medicine
Source: Streetwise Reports  (4/7/21)
Biohaven Pharmaceutical shares traded 10% higher after the company reported that in Q1/21 net product revenue for its migraine drug NURTEC ODT is estimated to be approximately $43.8 million. More >

Nano-X Imaging Receives Go Ahead from FDA for Single Source Digital X-Ray
Source: Streetwise Reports  (4/5/21)
Shares of Nano-X Imaging Ltd. traded 17% higher after the company reported that the FDA has granted 510(k) approval for its single source ARC digital x-ray. More >

United Therapeutics Shares Rise 15% as FDA Clears Pathway to Launch Tyvaso to Treat PH-ILD
Source: Streetwise Reports  (4/1/21)
United Therapeutics shares reached a new 52-week high after the firm reported that the U.S. FDA granted approval to commercially launch its Tyvaso® Inhalation Solution to treat patients with pulmonary hypertension associated with interstitial lung disease. More >

Coverage Initiated on Health & Wellness Firm About to Launch Retail Sales, Sees 'Substantial Upside Potential'
Source: Streetwise Reports  (3/30/21)
Clarus Securities' initiation report on Rritual Superfoods views the company "as an attractive growth story for investors looking to gain exposure to a large and rapidly growing functional food and beverages market." More >

Pharmaceutical Development Company Added to First Psychedelic Stock Index ETF
Source: Streetwise Reports  (3/30/21)
Being included in the Horizons Psychedelic Stock Index Exchange Traded Fund will afford Algernon Pharmaceuticals greater investor exposure. More >

Shockwave Medical Reports 100% Increase in Preliminary Q1 Revenue
Source: Streetwise Reports  (3/30/21)
Shockwave Medical Inc. shares gained 19% after the company announced that sales of its recently launched C2 Coronary IVL System are growing steadily and are driving revenue growth. More >

Data from Humanigen's Phase 3 COVID-19 Trial Show 54% Increase in Survival Rates
Source: Streetwise Reports  (3/29/21)
Shares of Humanigen Inc. traded 67% higher after the company reported positive topline results from its Phase 3 lenzilumabâ„¢ study indicating significant improvement in survival of hospitalized COVID-19 pneumonia patients without the need for mechanical ventilation. More >

ProQR Shares Gain 62% on Stellar Results in Phase 1/2 Usher Syndrome Trial
Source: Streetwise Reports  (3/25/21)
ProQR Therapeutics shares reached a new 52-week high after the company reported highly positive results from its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. More >

Biopharma to Request U.S. Emergency Use Authorization for COVID-19 Vaccine in April
Source: Streetwise Reports  (3/24/21)
Catalysts expected in 2021-2022 regarding Ocugen's pipeline therapeutics are discussed in a ROTH Capital Partners report. More >

Rritual Superfoods Hits the Superhighway to Nationwide Distribution and Impressive Share Gains
Source: Knox Henderson for Streetwise Reports  (3/24/21)
Knox Henderson delves into the value proposition behind Rritual Superfoods, which has just started trading this month. More >

Aptose Biosciences Shares Rise 55% on Q4 Financial Results and Promising Clinical Trials
Source: Streetwise Reports  (3/24/21)
Aptose Biosciences Inc. shares traded 55% higher after the company posted Q4 and FY/20 financial results and provided an update on the status of its drug candidates in ongoing clinical trials investigating treatments for life threatening hematologic cancers. More >

Investor Campbell Becher's Three Core Assets
Source: Streetwise Reports  (3/22/21)
The former Bay Street investment banker is finding himself going narrower and deeper. More >

Mental Health Firm Partners with Merck on Treatment-Resistant Depression Trial
Source: Streetwise Reports  (3/22/21)
Novamind Inc. reported it is teaming up with Merck to conduct a new Phase 2a study addressing treatment-resistant depression at a key clinical research site owned by its subsidiary company Cedar Clinical Research. More >

The Covid-19 Issue Too Many Are Ready to Overlook, and the Investing Opportunity It Creates
Source: KSS, MD, PhD, for Streetwise Reports  (3/22/21)
Have we forgotten about good Covid 19 Therapeutics? KSS MD PhD, editor-in-chief of PubBio.co, discusses three gems investors should know about. More >

Clovis Oncology Shares Rise on Positive Data from Phase 3 Ovarian Cancer Trial
Source: Streetwise Reports  (3/19/21)
Shares of Clovis Oncology Inc. traded 55% higher after it reported that in the Phase 3 ARIEL4 study Rubraca (rucaparib) significantly improved progression-free survival versus chemotherapy in patients with later-line ovarian cancer associated with a BRCA Mutation. More >